New Glucose-Lowering Agents for Diabetic Kidney Disease

Lisanne C. de Vos, Thushan S. Hettige, Mark E. Cooper

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents. This review elaborates on the main results of renoprotective effects of these 3 treatment classes. In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalAdvances in Chronic Kidney Disease
Volume25
Issue number2
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Chronic kidney disease
  • Diabetes mellitus
  • DPP-4 inhibitors
  • GLP-1 receptor agonists
  • SGLT-2 inhibitors

Cite this

de Vos, Lisanne C. ; Hettige, Thushan S. ; Cooper, Mark E. / New Glucose-Lowering Agents for Diabetic Kidney Disease. In: Advances in Chronic Kidney Disease. 2018 ; Vol. 25, No. 2. pp. 149-157.
@article{1a93663ac5504964a30baa86ce483205,
title = "New Glucose-Lowering Agents for Diabetic Kidney Disease",
abstract = "The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents. This review elaborates on the main results of renoprotective effects of these 3 treatment classes. In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made.",
keywords = "Chronic kidney disease, Diabetes mellitus, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors",
author = "{de Vos}, {Lisanne C.} and Hettige, {Thushan S.} and Cooper, {Mark E.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1053/j.ackd.2018.01.002",
language = "English",
volume = "25",
pages = "149--157",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "Elsevier",
number = "2",

}

New Glucose-Lowering Agents for Diabetic Kidney Disease. / de Vos, Lisanne C.; Hettige, Thushan S.; Cooper, Mark E.

In: Advances in Chronic Kidney Disease, Vol. 25, No. 2, 01.03.2018, p. 149-157.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - New Glucose-Lowering Agents for Diabetic Kidney Disease

AU - de Vos, Lisanne C.

AU - Hettige, Thushan S.

AU - Cooper, Mark E.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents. This review elaborates on the main results of renoprotective effects of these 3 treatment classes. In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made.

AB - The prevalence of diabetes mellitus is increasing and is associated with a range of complications including nephropathy. New antidiabetic agents are sought which also have positive effects to diminish diabetic complications. Examples of promising new classes of such agents are glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors. In addition to cardiovascular protective effects such as weight loss and decreased blood pressure of some of these agents, there is evidence for renoprotective effects with these agents. This review elaborates on the main results of renoprotective effects of these 3 treatment classes. In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made.

KW - Chronic kidney disease

KW - Diabetes mellitus

KW - DPP-4 inhibitors

KW - GLP-1 receptor agonists

KW - SGLT-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85044146767&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2018.01.002

DO - 10.1053/j.ackd.2018.01.002

M3 - Review Article

VL - 25

SP - 149

EP - 157

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 2

ER -